Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $100 price target.
Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $100 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.